title: Analysis of pilot and early phase studies with small sample sizes.
abstract: The need for statistical methodologies for analysing a small size study, such as a pilot or so-called 'proof of concept' study, has not been paid much attention in the past. Recently the Institute of Medicine (IOM) formed a committee and held a workshop to discuss methodologies for conducting clinical trials with small number participants. In this paper we argue that the hypothesis of treatment effect in a small pilot study should be set up to test whether any individual subject has an effect rather than whether the group mean or median has shifted as often done for large, confirmatory clinical trials. Based on this paradigm we propose multiple test procedures as one option when individuals have enough observations, and a mixture-distribution approach when individuals have one or more observations. The latter approach may be used in either a one- or two-group setting, and is our focus in this paper. We present the likelihood ratio tests for the mixture models. Examples are given to demonstrate the methods.
authors.affiliation: Division of Biometrics, School of Public Health and Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, 683 Hoes Lane West, P.O. Box 9, Piscataway, NJ 08854 USA. shihwj@umdnj.edu
authors.forename: Weichung Joseph
authors.initials: WJ
authors.lastname: Shih
authors.forename: Pamela A
authors.initials: PA
authors.lastname: Ohman-Strickland
authors.forename: Yong
authors.initials: Y
authors.lastname: Lin
mesh_terms: D017321:Clinical Trials, Phase I as Topic / Q000379:methods*; D003198:Computer Simulation; D003627:Data Interpretation, Statistical; D004359:Drug Therapy, Combination; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use; D015474:Isotretinoin / Q000494:pharmacology / Q000627:therapeutic use; D016013:Likelihood Functions; D008297:Male; D018923:Persian Gulf Syndrome / Q000209:etiology / Q000473:pathology; D010865:Pilot Projects; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy; D016212:Transforming Growth Factor beta / Q000097:blood; D001335:Vehicle Emissions / Q000009:adverse effects
chemical_list: D016898:Interferon-alpha; D016212:Transforming Growth Factor beta; D001335:Vehicle Emissions; D017430:Prostate-Specific Antigen; D015474:Isotretinoin